EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Circulating Blood Prognostic Biomarker Signatures for Hemorrhagic Cerebral Cavernous Malformations (CCMs)

Jacob Croft, Brian Grajeda iD, Luis A Aguirre, Johnathan S Abou-Fadel, Cameron C Ellis iD, Igor Estevao iD, Igor C Almeida, Jun Zhang iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25094740 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Jacob Croft und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular and Translational Medicine, Texas Tech University Health Science Center El Paso (TTUHSCEP), El Paso, TX 79905, USA. Hauptthemen laut MEDLINE: Hemangioma, Cavernous, Central Nervous System, Biomarkers. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 97 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIMHD NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cerebral cavernous malformations (CCMs) are a neurological disorder characterized by enlarged intracranial capillaries in the brain, increasing the susceptibility to hemorrhagic strokes, a major cause of death and disability worldwide. The limited treatment options for CCMs underscore the importance of prognostic biomarkers to predict the likelihood of hemorrhagic events, aiding in treatment decisions and identifying potential pharmacological targets. This study aimed to identify blood biomarkers capable of diagnosing and predicting the risk of hemorrhage in CCM1 patients, establishing an initial set of circulating biomarker signatures. By analyzing proteomic profiles from both human and mouse CCM models and conducting pathway enrichment analyses, we compared groups to identify potential blood biomarkers with statistical significance. Specific candidate biomarkers primarily associated with metabolism and blood clotting pathways were identified. These biomarkers show promise as prognostic indicators for CCM1 deficiency and the risk of hemorrhagic stroke, strongly correlating with the likelihood of hemorrhagic cerebral cavernous malformations (CCMs). This lays the groundwork for further investigation into blood biomarkers to assess the risk of hemorrhagic CCMs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemangioma, Cavernous, Central Nervous SystemBiomarkersHumansAnimalsMicePrognosisProteomicsCerebral HemorrhageKRIT1 ProteinDisease Models, AnimalFemaleMale

Stichwörter der Autor:innen

cerebral cavernous malformations (CCMs)circulating blood biomarkerhemorrhagic strokeprognostic and predictive biomarkers

Substanzen

BiomarkersKRIT1 Protein

Autor:innen und Institutionen

  • Department of Molecular and Translational Medicine, Texas Tech University Health Science Center El Paso (TTUHSCEP), El Paso, TX 79905, USA.
  • Department of Biological Sciences, University of Texas at El Paso, El Paso, TX 79902, USA.

ORCID-Profile: Brian Grajeda, Cameron C Ellis, Igor Estevao, Jun Zhang

Förderung

  • NIMHD NIH HHS

Zitieren

APA

Croft, J., Grajeda, B., Aguirre, L. A., Abou-Fadel, J. S., Ellis, C. C., Estevao, I., Almeida, I. C., & Zhang, J. (2024). Circulating Blood Prognostic Biomarker Signatures for Hemorrhagic Cerebral Cavernous Malformations (CCMs). International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25094740

Vancouver

Croft J, Grajeda B, Aguirre LA, Abou-Fadel JS, Ellis CC, Estevao I, et al. Circulating Blood Prognostic Biomarker Signatures for Hemorrhagic Cerebral Cavernous Malformations (CCMs). International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25094740

BibTeX
@article{Croft2024,
  author = {Croft, Jacob and Grajeda, Brian and Aguirre, Luis A and Abou-Fadel, Johnathan S and Ellis, Cameron C and Estevao, Igor and Almeida, Igor C and Zhang, Jun},
  title = {Circulating Blood Prognostic Biomarker Signatures for Hemorrhagic Cerebral Cavernous Malformations (CCMs)},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25094740}
}
Kostenlos starten →